Rega marang bathi mangsa ngarep: Syros Pharmaceuticals (SYRS)
The market for targeted gene regulation in leukemia is highly promising due to a lack of alternatives. The forward P/E valuation trend for Syros Pharmaceuticals (SYRS) on the GURU.Markets summary chart, where the parameter value equals 0.00, is based on a unique cancer cell reprogramming platform. The Syros Pharmaceuticals business is non-cyclical, although it remains sensitive to the cost of debt when seeking liquidity.
Rincian metrik keuangan lan pasar Syros Pharmaceuticals (SYRS)
- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
- data ekuitas miturut neraca:
- rincian utang lan likuiditas:
Total Utang marang Modal Syros Pharmaceuticals|SYRS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal syros.com|SYRS - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Syros Pharmaceuticals|SYRS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Syros Pharmaceuticals|Rasio cepet syros.com
- rincian asil keuangan lan kelipatan valuasi:
SYRS - Bathi resik|Proyeksi bathi mangsa ngarep Syros Pharmaceuticals|SYRS - Koefisien rega marang bathi|Pangali Forward P/E Syros Pharmaceuticals Inc.|SYRS - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Syros|SYRS - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Syros Pharmaceuticals|SYRS - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan syros.com|SYRS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Syros Pharmaceuticals
- informasi babagan volume dodolan lan pendapatan:
Analisis komprehensif perusahaan:SYRS Syros
Adherence to biomedical research ethical standards and the environmental safety of Syros Pharmaceuticals (SYRS) laboratories establish the foundation for long-term business sustainability. This stability correlates with the forward P/E, which determines the cost per unit of expected earnings, allowing investors to assess the premium paid for future success by analyzing the issuer's forward P/E for potential market overvaluation of the asset.
Pesaing langsung
Prakiraan rega marang bathi TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Pangali forward rega marang bathi|Rega marang bathi mangsa ngarep ionispharma.com IONS|Kapitalisasi marang proyeksi bathi Repligen Corporation (RGEN)|RNA: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRSP (CRISPR Therapeutics Corp)|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Pangali Forward P/E|SRPT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Twist Bioscience Corp (TWST)|Prakiraan rega marang bathi 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi STOK|BLFS - Rega marang bathi mangsa ngarep|Wave Life Sciences (WVE) - Prakiraan rega marang bathi|MAZE: Pangali Forward P/E|Sionna Therapeutics, Inc. (SION) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Prime Medicine, Inc.|TSHA (Taysha) - Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi QURE (uniQure Pharma)|Kapitalisasi marang proyeksi bathi meiragtx.com|Rega marang bathi mangsa ngarep REGENXBIO RGNX|SLDB - Prakiraan rega marang bathi|Ocugen, Inc. - Pangali Forward P/E|PACB (Pacific Biosciences of California) - Rasio rega marang bathi mangsa ngarep|BNTC: Pangali Forward P/E|DSGN - Kapitalisasi marang proyeksi bathi|RCKT (Rocket Pharma) - Pangali Forward P/E|Rega marang bathi mangsa ngarep FDMT|Rega marang bathi mangsa ngarep Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Rasio rega marang bathi mangsa ngarep|editasmedicine.com - Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi silence-therapeutics.com (SLN)|PRQR: Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi codexis.com|SGMO: Pangali Forward P/E|Rasio prakiraan rega marang bathi Nautilus Biotechnology Inc (NAUT)|Prakiraan rega marang bathi MGX|DTIL (Precision BioSciences) - Rasio kapitalisasi marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Generation Bio Corp (GBIO)|Boundless Bio - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Exicure, Inc. XCUR|Pangali mangsa ngarep rega marang bathi IMNN|PHIO - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Mustang Bio Inc MBIO|RNAZ: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep BNGO|APDN (Applied DNA Sciences Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Bluebird Bio BLUE|Pangali Forward P/E IPA|Omega Therapeutics (OMGA) - Pangali forward rega marang bathi|Pangali Forward P/E OMIC (Singular Genomics Systems Inc)|Pangali forward rega marang bathi Regulus Therapeutics Inc|TBIO: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi TCON (TRACON)|UBX: Pangali Forward P/E
